International PR

press release

Title The World's First Exosome-Based Treatment for Atopic Dermatis
writer exocobio
date 2020-07-30

ExoCoBio published Research Paper on 'The World's First

Exosome-Based Treatment for Atopic Dermatis'



  ExoCoBio Inc., based in South Korea, published a scientific


paper on that stem cell-derived exosomes dramatically relieves


atopic dermatitis and inhibits a variety of inflammatory targets in


the journal of Stem Cell Research and Therapy.



  According to the paper, the symptoms of mice having severe


atopic dermatitis were significantly improved  after administration of


stem cell-derived exosomes intravenously or subcutaneously, so that


the level of serum immunoglobulin E (IgE), the number of eosinophils


in blood, and the number of mast cells in the skin lesion were


decreased. It has also been found that the number of inflammatory


dendritic epidermal cells (IDECs), which are not found in normal skin


but cause an allergic inflammatory response in atopic dermatitis


lesions, also significantly decreased to a normal skin level after


administration of stem cell-derived exosomes. In addition, the


improvement of the symptoms by stem cell-derived exosomes


was comparable to that of a steroid drug, Prednisolone.




                                                                                                                         <CISION> PRweb 2018. 8.24


´Ù¿î·Îµå¼ö 0